CSIMarket Company Name, Ticker, Customers, else..
 

Nrx Pharmaceuticals Inc   (NASDAQ: NRXP)

Nrx Pharmaceuticals Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

NRXP Sales vs. its Competitors Q2 2026


Comparing the current results to its competitors, Nrx Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year.
The revenue growth was below Nrx Pharmaceuticals Inc 's competitors' average revenue growth of 18.02 %, achieved in the same quarter.

• List of NRXP Competitors





Revenue Growth Comparisons




Net Income Comparison

Nrx Pharmaceuticals Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<<  NRXP Stock Performance Comparisons


Nrx Pharmaceuticals Inc 's Comment on Competition and Industry Peers


The competitive landscape includes the potential effects of comparative effectiveness research on the sales of product candidates. Third-party payers may limit coverage or provide inadequate reimbursement if products are not deemed cost-effective relative to other therapies. Legislative and regulatory changes in the United States and internationally may impact product profitability. Under the Hatch-Waxman Act, patents must be listed in the FDA's Orange Book upon drug approval. Competitors may reference these patents to seek approval of Abbreviated New Drug Applications (ANDAs) or 505(b)(2) New Drug Applications (NDAs) for generic equivalents. ANDA applicants are required to demonstrate bioequivalence but are not obligated to submit additional preclinical or clinical safety or effectiveness data.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Nrx Pharmaceuticals Inc




Xenon Pharmaceuticals Inc
Share Performance



-1.70%
Over The Past 5 Days
Xenon Pharmaceuticals Inc
Profile

Xenon Pharmaceuticals Inc operates in the biopharmaceutical industry, with a focus on discovering and developing innovative therapeutics. Their business model centers around leveraging their proprietary discovery platform to identify and advance potential drug candidates to address unmet medical needs. Through collaborations, licensing agreements, and internal development efforts, Xenon aims to bring new treatments to patients and create value for their stakeholders.

More about Xenon Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 5,874.986 mill. $ - mill. $ -409.195 mill.


Ironwood Pharmaceuticals inc
Share Performance



-4.68%
This Year
Ironwood Pharmaceuticals inc
Profile

Ironwood Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of medicines for gastrointestinal disorders. Their business model involves discovering, developing, and marketing innovative treatments for conditions like irritable bowel syndrome and chronic constipation. They aim to achieve growth and profitability by leveraging their research capabilities and collaborating with strategic partners in the healthcare industry.

More about Ironwood Pharmaceuticals inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 680.419 mill. $ 389.316 mill. $ 129.868 mill.


Opus Genetics Inc
Share Performance



+30.56%
Over The Past 5 Days
Opus Genetics Inc
Profile

Opus Genetics develops gene therapies for inherited retinal diseases and other ophthalmic disorders.

More about Opus Genetics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 647.141 mill. $ 9.856 mill. $ -114.997 mill.


Indivior Pharmaceuticals Inc
Share Performance



-7.56%
This Quarter
Indivior Pharmaceuticals Inc
Profile

The company develops, markets, and sells pharmaceutical products.

More about Indivior Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 4,485.330 mill. $ 1,292.000 mill. $ 252.000 mill.


Gossamer Bio Inc
Share Performance



-13.98%
This Quarter
Gossamer Bio Inc
Profile

Gossamer Bio Inc operates with a business model focused on the development and commercialization of novel therapies for patients with complex diseases. They leverage extensive scientific expertise and strategic partnerships to identify and advance a diverse pipeline of innovative medicines. Their goal is to deliver transformative therapies that address significant unmet medical needs and improve patient outcomes.

More about Gossamer Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 46.949 mill. $ 53.286 mill. $ -123.445 mill.

32 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Nrx Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Nrx Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.